Strut Coverage With SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial compared SYNERGY stents to a bioresorbable scaffold in heart attack patients and looked at how many stent struts were left uncovered at 3 months — what does incomplete strut coverage actually mean for my risk of complications like blood clots, and how does that apply to my specific situation?
2. 2Since this trial has already completed and was measuring strut coverage rather than longer-term outcomes like heart attack recurrence or survival, does the available data tell us anything meaningful about which type of stent might be safer or more effective for me over time?
3. 3The trial was listed as Phase NA, which often means it was more of an observational or device comparison study rather than a traditional drug trial — how confident are you in the evidence behind whichever stent type you're recommending for my procedure?
4. 4Given that this study enrolled acute coronary syndrome patients specifically, and my diagnosis fits that category, how do you weigh the findings from this trial against current standard-of-care guidelines when deciding which stent to use for me?
5. 5Bioresorbable scaffolds were one of the devices studied here, and they've had a mixed history in real-world use — is a bioresorbable option still something worth considering in my case, or has more recent evidence shifted your thinking toward a traditional stent?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.